Disrupted Lipid Metabolism, Cytokine Signaling, and Dormancy: Hallmarks of Doxorubicin-Resistant Triple-Negative Breast Cancer Models

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2025 Jan 8

PMID 39766172

Authors

Radhakrishnan Vishnubalaji

Nehad M Alajez

Affiliations

Soon will be listed here.

Abstract

Background: Chemoresistance in triple-negative breast cancer (TNBC) presents a significant clinical hurdle, limiting the efficacy of treatments like doxorubicin. This study aimed to explore the molecular changes associated with doxorubicin resistance and identify potential therapeutic targets to overcome this resistance, thereby improving treatment outcomes for TNBC patients.

Methods: Doxorubicin-resistant (DoxR) TNBC models (MDA-MB-231 and BT-549) were generated by exposing cells to increasing concentrations of doxorubicin. RNA sequencing (RNA-Seq) was performed using the Illumina platform, followed by bioinformatics analysis with CLC Genomics Workbench and iDEP. Functional assays assessed proliferation, sphere formation, migration, and cell cycle changes. Protein expression and phosphorylation were confirmed via Western blotting. Pathway and network analyses were conducted using Ingenuity Pathway Analysis (IPA) and STRING, while survival analysis was performed using Kaplan-Meier Plotter database.

Results: DoxR cells exhibited reduced proliferation, sphere formation, and migration, but showed enhanced tolerance to doxorubicin. Increased CHK2 and p53 phosphorylation indicated cellular dormancy as a resistance mechanism. RNA-Seq analysis revealed upregulation of cytokine signaling and stress-response pathways, while cholesterol and lipid biosynthesis were suppressed. Activation of the IL1β cytokine network was prominent in DoxR cells, and CRISPR-Cas9 screens data identified dependencies on genes involved in rRNA biogenesis and metabolism. A 27-gene signature associated with doxorubicin resistance was linked to worse clinical outcomes in a large breast cancer cohort (HR = 1.76, FDR < 2.0 × 10).

Conclusions: This study uncovers potential therapeutic strategies for overcoming TNBC resistance, including dormancy reversal and targeting onco-ribosomal pathways and cytokine signaling networks, to improve the efficacy of doxorubicin-based treatments.

References

Bjarnadottir O, Romero Q, Bendahl P, Jirstrom K, Ryden L, Loman N . Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat. 2013; 138(2):499-508. DOI: 10.1007/s10549-013-2473-6. View

Pritchard K, Messersmith H, Elavathil L, Trudeau M, OMalley F, Dhesy-Thind B . HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol. 2008; 26(5):736-44. DOI: 10.1200/JCO.2007.15.4716. View

Derenzini M, Montanaro L, Trere D . What the nucleolus says to a tumour pathologist. Histopathology. 2009; 54(6):753-62. DOI: 10.1111/j.1365-2559.2008.03168.x. View

Burgess D, Doles J, Zender L, Xue W, Ma B, McCombie W . Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A. 2008; 105(26):9053-8. PMC: 2435590. DOI: 10.1073/pnas.0803513105. View

Hyun S, Jang Y . p53 activates G₁ checkpoint following DNA damage by doxorubicin during transient mitotic arrest. Oncotarget. 2015; 6(7):4804-15. PMC: 4467116. DOI: 10.18632/oncotarget.3103. View

Tulotta C, Lefley D, Moore C, Amariutei A, Spicer-Hadlington A, Quayle L . IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer. NPJ Breast Cancer. 2021; 7(1):95. PMC: 8295314. DOI: 10.1038/s41523-021-00305-w. View

Volarevic S, Stewart M, Ledermann B, Zilberman F, Terracciano L, Montini E . Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6. Science. 2000; 288(5473):2045-7. DOI: 10.1126/science.288.5473.2045. View

Garrido-Castro A, Lin N, Polyak K . Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019; 9(2):176-198. PMC: 6387871. DOI: 10.1158/2159-8290.CD-18-1177. View

Tentori L, Graziani G . Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res. 2005; 52(1):25-33. DOI: 10.1016/j.phrs.2005.02.010. View

10.

Soureas K, Papadimitriou M, Panoutsopoulou K, Pilala K, Scorilas A, Avgeris M . Cancer quiescence: non-coding RNAs in the spotlight. Trends Mol Med. 2023; 29(10):843-858. DOI: 10.1016/j.molmed.2023.07.003. View

11.

Wei J, Sun H, Zhang A, Wu X, Li Y, Liu J . A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers. Cell Immunol. 2018; 331:49-58. DOI: 10.1016/j.cellimm.2018.05.004. View

12.

Trudeau M, Charbonneau F, Gelmon K, Laing K, Latreille J, Mackey J . Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol. 2005; 6(11):886-98. DOI: 10.1016/S1470-2045(05)70424-1. View

13.

Gorgoulis V, Adams P, Alimonti A, Bennett D, Bischof O, Bishop C . Cellular Senescence: Defining a Path Forward. Cell. 2019; 179(4):813-827. DOI: 10.1016/j.cell.2019.10.005. View

14.

Carey L, Rugo H, Marcom P, Mayer E, Esteva F, Ma C . TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012; 30(21):2615-23. PMC: 3413275. DOI: 10.1200/JCO.2010.34.5579. View

15.

Henderson I, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S . Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21(6):976-83. DOI: 10.1200/JCO.2003.02.063. View

16.

Gewirtz D . A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999; 57(7):727-41. DOI: 10.1016/s0006-2952(98)00307-4. View

17.

Clendening J, Pandyra A, Boutros P, El Ghamrasni S, Khosravi F, Trentin G . Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A. 2010; 107(34):15051-6. PMC: 2930553. DOI: 10.1073/pnas.0910258107. View

18.

Vishnubalaji R, Alajez N . Transcriptional landscape associated with TNBC resistance to neoadjuvant chemotherapy revealed by single-cell RNA-seq. Mol Ther Oncolytics. 2021; 23:151-162. PMC: 8517543. DOI: 10.1016/j.omto.2021.09.002. View

19.

Sharma S, Lee D, Li B, Quinlan M, Takahashi F, Maheswaran S . A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010; 141(1):69-80. PMC: 2851638. DOI: 10.1016/j.cell.2010.02.027. View

20.

Recasens A, Munoz L . Targeting Cancer Cell Dormancy. Trends Pharmacol Sci. 2019; 40(2):128-141. DOI: 10.1016/j.tips.2018.12.004. View